SEC Form 4 · accession 0001437749-26-028840
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Schoenberg
Officer — Chief Medical Officer
Period of report
Aug 20, 2026
Accepted (ET)
Aug 24, 2026 · 5:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ordinary sharesF1 | Aug 20, 2026 | S | 60,677 | $47.05 | D | 59,086 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $49.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.